<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02592629</url>
  </required_header>
  <id_info>
    <org_study_id>2690</org_study_id>
    <nct_id>NCT02592629</nct_id>
  </id_info>
  <brief_title>The Efficacy of Local Anesthetics to Reduce Shoulder Pain Post-Steroid Injections</brief_title>
  <official_title>The Efficacy of Local Anesthetics to Reduce Shoulder Pain Post-Steroid Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific aim of this prospective study is to determine whether local anesthetics prior to
      subacromial steroid injections reduce pain and consequently if they are cost-effective in the
      treatment for shoulder pathology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Shoulder pain is a common problem that can be estimated to be prevalent in up to 15 percent
      of the patient population registered to general practices and is second only to back pain in
      patients seeking treatment for musculoskeletal issues in the primary care setting. As a
      common source of distress, shoulder pain contributes significantly to health care costs.

      Rotator cuff disease due to impingement, tendonitis or bursitis is a frequent cause of
      shoulder pain and dysfunction. Initial treatment consists of a conservative approach of
      activity modification, oral nonsteroidal anti-inflammatory drugs (NSAIDs) and supervised
      physical therapy. However, if the patients' symptoms persist, subacromial injections of a
      local anesthetic such as lidocaine, and a corticosteroid may be indicated as a sequential
      treatment option.

      The steroid injection itself can be a painful process, so administering a local anesthetic
      prior to the steroid injection is thought to mitigate pain or reduce possible discomfort
      during and immediately following the procedure. Though there is evidence advocating for the
      benefits of combining local anesthetics and corticosteroids for the treatment of subacromial
      pathologies, it is not conclusive whether local anesthesia significantly enhances the pain
      relieving effect of steroids. Should local anesthesia not have a significant impact on the
      patient's pain intensity, then the use of corticosteroids alone could potentially result in
      reduced costs in care.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of time to enroll due to additional responsibilities of the PI and research coordinator.
  </why_stopped>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Actual">June 20, 2017</completion_date>
  <primary_completion_date type="Actual">June 20, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Assessment</measure>
    <time_frame>change from baseline assessment before injection at 10 minutes post injection</time_frame>
    <description>Pain assessed on a visual analog scale from 1 (no pain) to 10 (worst pain imaginable). Pain score at 10 minutes post-injection is subtracted from baseline pre-injection score. Positive numbers to represent increases and negative numbers to represent decreases.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Shoulder Pain</condition>
  <arm_group>
    <arm_group_label>no topical or subcutaneous anesthetic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>subcutaneous lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after 2 ml or 1% lidocaine by subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>topical ethyl chloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after applying ethyl chloride spray for 3 seconds</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine</intervention_name>
    <description>used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection</description>
    <arm_group_label>no topical or subcutaneous anesthetic</arm_group_label>
    <arm_group_label>subcutaneous lidocaine</arm_group_label>
    <arm_group_label>topical ethyl chloride</arm_group_label>
    <other_name>xylocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ethyl chloride</intervention_name>
    <description>topical spray</description>
    <arm_group_label>topical ethyl chloride</arm_group_label>
    <other_name>chloroethane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kenalog</intervention_name>
    <description>used with lidocaine in shoulder injection</description>
    <arm_group_label>no topical or subcutaneous anesthetic</arm_group_label>
    <arm_group_label>subcutaneous lidocaine</arm_group_label>
    <arm_group_label>topical ethyl chloride</arm_group_label>
    <other_name>triamcinolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18 to 70 years old

          -  Shoulder pain lasting at least 4 weeks

          -  Inability to use arm with restriction of movement and loss of full function.

          -  Able to understand study and provide voluntary, written informed consent

        Exclusion Criteria:

          -  Less than 18 or greater than 70 years old

          -  Contraindications of previous injections and previous shoulder surgery

          -  Unable to understand consent form (in the opinion of the PI)

          -  Non-English speaking individuals

          -  Medication contradictions to lidocaine, corticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Gallo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>October 28, 2015</study_first_submitted>
  <study_first_submitted_qc>October 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2015</study_first_posted>
  <results_first_submitted>June 20, 2018</results_first_submitted>
  <results_first_submitted_qc>August 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2018</results_first_posted>
  <last_update_submitted>September 17, 2018</last_update_submitted>
  <last_update_submitted_qc>September 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Robert A. Gallo</investigator_full_name>
    <investigator_title>Assistant Professor of Surgery Orthopaedics</investigator_title>
  </responsible_party>
  <keyword>subacromial injection</keyword>
  <keyword>rotator cuff disease</keyword>
  <keyword>steroid injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shoulder Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Ethyl Chloride</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT02592629/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT02592629/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>no Topical or Subcutaneous Anesthetic</title>
          <description>Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine
lidocaine: used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
Kenalog: used with lidocaine in shoulder injection</description>
        </group>
        <group group_id="P2">
          <title>Subcutaneous Lidocaine</title>
          <description>Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after 2 ml or 1% lidocaine by subcutaneous injection
lidocaine: used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
Kenalog: used with lidocaine in shoulder injection</description>
        </group>
        <group group_id="P3">
          <title>Topical Ethyl Chloride</title>
          <description>Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after applying ethyl chloride spray for 3 seconds
lidocaine: used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
ethyl chloride: topical spray
Kenalog: used with lidocaine in shoulder injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>no Topical or Subcutaneous Anesthetic</title>
          <description>Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine
lidocaine: used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
Kenalog: used with lidocaine in shoulder injection</description>
        </group>
        <group group_id="B2">
          <title>Subcutaneous Lidocaine</title>
          <description>Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after 2 ml or 1% lidocaine by subcutaneous injection
lidocaine: used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
Kenalog: used with lidocaine in shoulder injection</description>
        </group>
        <group group_id="B3">
          <title>Topical Ethyl Chloride</title>
          <description>Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after applying ethyl chloride spray for 3 seconds
lidocaine: used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
ethyl chloride: topical spray
Kenalog: used with lidocaine in shoulder injection</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>baseline pain</title>
          <description>The pain will be measured with a scale from 0 (no pain) to 10 (worst possible pain)&quot;.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" spread="2.56"/>
                    <measurement group_id="B2" value="5.16" spread="1.93"/>
                    <measurement group_id="B3" value="4.7" spread="1.84"/>
                    <measurement group_id="B4" value="4.78" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Assessment</title>
        <description>Pain assessed on a visual analog scale from 1 (no pain) to 10 (worst pain imaginable). Pain score at 10 minutes post-injection is subtracted from baseline pre-injection score. Positive numbers to represent increases and negative numbers to represent decreases.</description>
        <time_frame>change from baseline assessment before injection at 10 minutes post injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>no Topical or Subcutaneous Anesthetic</title>
            <description>Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine
lidocaine: used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
Kenalog: used with lidocaine in shoulder injection</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Lidocaine</title>
            <description>Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after 2 ml or 1% lidocaine by subcutaneous injection
lidocaine: used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
Kenalog: used with lidocaine in shoulder injection</description>
          </group>
          <group group_id="O3">
            <title>Topical Ethyl Chloride</title>
            <description>Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after applying ethyl chloride spray for 3 seconds
lidocaine: used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
ethyl chloride: topical spray
Kenalog: used with lidocaine in shoulder injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Assessment</title>
          <description>Pain assessed on a visual analog scale from 1 (no pain) to 10 (worst pain imaginable). Pain score at 10 minutes post-injection is subtracted from baseline pre-injection score. Positive numbers to represent increases and negative numbers to represent decreases.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="1.6"/>
                    <measurement group_id="O2" value="4.21" spread="2.19"/>
                    <measurement group_id="O3" value="5.6" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>no Topical or Subcutaneous Anesthetic</title>
          <description>Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine
lidocaine: used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
Kenalog: used with lidocaine in shoulder injection</description>
        </group>
        <group group_id="E2">
          <title>Subcutaneous Lidocaine</title>
          <description>Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after 2 ml or 1% lidocaine by subcutaneous injection
lidocaine: used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
Kenalog: used with lidocaine in shoulder injection</description>
        </group>
        <group group_id="E3">
          <title>Topical Ethyl Chloride</title>
          <description>Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after applying ethyl chloride spray for 3 seconds
lidocaine: used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
ethyl chloride: topical spray
Kenalog: used with lidocaine in shoulder injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Gallo, M.D.</name_or_title>
      <organization>Penn State Hershey Medical Center</organization>
      <phone>7175310003 ext 289222</phone>
      <email>rgallo@pennstatehershey.psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

